KT-295

KT-295 is an investigational, first-in-class, once-daily oral small molecule degrader of tyrosine kinase 2 (TYK2), a member of the Janus kinase (JAK) family required for Type I interferon (IFN), interleukin-12 (IL-12), and interleukin-23 (IL-23) signaling. Developed by Kymera Therapeutics, KT-295 is designed to selectively degrade TYK2 protein, thereby blocking key inflammatory pathways implicated in autoimmune and inflammatory diseases. Preclinical studies have shown that KT-295 can replicate the human genetic loss-of-function profile of TYK2 and block these pathways similarly to upstream biologics. The drug aims to deliver biologics-like efficacy in an oral formulation for diseases such as inflammatory bowel disease (IBD), psoriasis, psoriatic arthritis, and systemic lupus erythematosus. As of early 2025, it is advancing toward Phase 1 clinical trials in healthy volunteers[1][3][4][5][6][8].

Other names

KT 295KT295KT-295